Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis - Amrane, K.; Cabarrou, B.; Justeau, G.; Schneider, S.; Quantin, X.; Falchero, L.; Bigot, F.; Ferrari, V.; Guisier, F.; Girard, N.; Lena, H.; Dansin, E.; et al. (ESMO open, 2025)
Keywords: Aged; Cancer; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; chemotherapy; Female; France; Humans; Immune Checkpoint Inhibitors - therapeutic use; immunotherapy; Life Sciences; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Middle Aged; NSCLC; Oncology; Original; PD-L1; pulmonary sarcomatoid carcinoma; Treatment Outcome; France; PD-L1; NSCLC; pulmonary sarcomatoid carcinoma; chemotherapy; immunotherapy